Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Synopsys, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Synopsys, Inc. trades at $454.05 (market cap $85.30B). The key difference: Synopsys, Inc. is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Synopsys, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SNPS | |
|---|---|---|
Market Cap | $39.89B | $85.30B |
Sector | Health | Technology |
52-Week High | $491.22 | $645.59 |
52-Week Low | $278.09 | $380.47 |
Enterprise Value | $38.15B | $93.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Synopsys (SNPS) trades at $445.40, up 0.5% on the day, amid a bearish technical signal with support at $432 and resistance at $449. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.35 versus $3.15 expected, and robust revenue growth to $7.05B in 2025. However, net income margin declined to 8.91% from 36.93% in 2024, and cash flow turned negative at -$1.01B due to heavy investing activity.
Outlook remains positive with analyst consensus price target of $558.33 implying 25% upside, supported by the company's strategic pivot to AI-driven design tools. Key risks include execution of the AI transition, high valuation multiples like a P/E of 101.95, and semiconductor cycle volatility. The stock offers growth exposure but requires monitoring of margin trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
